Unitiol - instructions for use, dose, side effects, contraindications

Active substance:
Sodium dimercaptopropanesulfonate monohydrate (unitiol) (in terms of 100% substance)	- 50 mg
Excipient:
Water for injections	- up to 1 ml

Description:

Transparent, colorless or pinkish liquid with a faint smell of hydrogen sulphide.

Pharmacotherapeutic group:Complexing agent

ATX: & nbsp

V.03.A.B Antidotes

Pharmacodynamics:

Complexing agent, has detoxification effect. Active sulfhydryl groups, reacting with thiol poisons (arsenic compounds, heavy metal salts) and forming non-toxic water-soluble compounds with them, restore the functions of the enzyme systems of the organism affected by the poison.Increases the excretion of certain cations (especially copper and zinc) from metal-containing cell enzymes.

Pharmacokinetics:

When parenteral administration is rapidly absorbed into the blood. The maximum concentration in the blood plasma (C_mOh) is achieved 15-30 minutes after intramuscular injection. The half-life (T_1/2) is from 1 to 2 hours. The volume of distribution is 166.5 ml / kg. The drug is distributed mainly in the aqueous phase (blood plasma), widely distributed in the tissues of the body, the highest concentrations found in the kidneys and liver. Not cumulated. Excreted by the kidneys, mainly in the form of partial or partial oxidation products, partially unchanged. Excreted also with bile. Eliminated within 4 hours after applying a single dose.

Indications:

Intoxication with arsenic, mercury, bismuth, chromium, gold, antimony, thallium, cardiac glycosides; hepatocerebral dystrophy (Wilson-Westfal-Konovalov disease); chronic alcoholism and alcoholic delirium (as part of complex therapy).

Contraindications:

Hypersensitivity, hepatic insufficiency, arterial hypertension, pregnancy, lactation, age under 18.

With the development of renal failure, the drug should be discontinued or applied with extreme caution.

Carefully:

Long-term use of the drug should be carried out under the constant supervision of the excretion of heavy metals by the kidneys.

Pregnancy and lactation:

The drug is contraindicated in pregnancy and during breastfeeding.

Dosing and Administration:

Intramuscularly, subcutaneously.

With intoxication with arsenic: from 250 to 500 mg (from 5 to 10 ml of the drug), at the rate of 50 mg / 10 kg, on the first day from 3 to 4 times, on the second day from 2 to 3 times, in the subsequent days - from 1 to 2 times.

When poisoning with mercury compounds: for the same scheme for 6-7 days. Treatment is carried out until the signs of intoxication disappear.

With digital intoxication: in the first two days, 250 to 500 mg (5 to 10 ml of the drug) are administered 3 to 4 times a day, then 1 to 2 times a day until the cardiotoxic action stops.

In hepatocerebral dystrophy: intramuscularly from 250 to 500 mg (from 5 to 10 ml of the drug) daily or every other day; course of treatment from 25 to 30 injections; if necessary, repeat the course after 3-4 months.

In chronic alcoholism prescribe from 150 to 250 mg (3 to 5 ml of the drug) 2 to 3 times a week.

For the relief of delirium: once from 200 to 250 mg (from 4 to 5 ml of the drug).

Side effects:

Allergic reactions are possible.

Nausea, dizziness, tachycardia, pale skin.

Increased arterial blood pressure, vomiting, headache, burning sensation in the lips, mouth and throat, a feeling of restraint and pain in the throat, chest and hands, conjunctivitis, lacrimation, spasm of the eyelids, rhinorrhea, drooling, tingling in the hands, burning sensation in the sweating of the forehead, brushes and other areas, abdominal pain, anxiety, weakness, anxiety, hemolysis, transient leukocytopenia, tremor, burning eyes, hepatotoxicity, spasms and muscle pain, pain in the jaw, kidney failure, hyperthermia, pain at the injection site, about the activation of activated partial thromboplastin time, the decrease in the concentration of zinc in the blood.

When applying high doses of the drug, a sharp increase in arterial blood pressure with convulsions and coma may occur.

When the drug is administered in a therapeutic dose, undesirable reactions are almost always reversible and are rarely serious enough to stop the drug administration.Reduction of the level of undesirable reactions is possible if the time interval between injections of the preparation is 4 hours.

If any of the side effects indicated in the instructions are aggravated, or any other side effects not indicated in the instructions are noted, the physician should decide whether to correct the scheme for further treatment.

Overdose:

In the recommended doses and on the evidence of overdose phenomena does not arise. When the recommended therapeutic dose is increased by 10 times, dyspnea, hyperkinesia, inhibition, lethargy, dizziness, short-term convulsions are observed.

Possible treatment: subcutaneous injection of diphenhydramine 50 mg or 30 mg ephedrine.

Interaction:

The simultaneous use of Unithiol with preparations containing heavy metals and alkalis is not recommended, since Uniothiol rapidly decomposes.

Special instructions:

In case of acute poisoning, additional medical measures are carried out (gastric lavage, oxygen therapy, dextrose administration, etc.).

Simultaneous use with iron preparations is not allowed.

When used, therapy is recommended leading to alkalization of the resulting urine.in an acidic environment, the sodium-metal dimercaptopropanesulfonate complex is unstable.

There is insufficient evidence of the effectiveness of the drug in bismuth and antimony poisoning.

The drug is effective in acute poisoning with mercury (if therapy is started within 1-2 hours after poisoning), the drug is ineffective in chronic mercury poisoning.

It is inadmissible to use the drug for iron, cadmium, selenium poisoning, since their complexes with unithiol are more toxic than the metals themselves, especially for the kidneys.

When using the drug, a transient decrease in the percentage of polymorphonuclear leukocytes is possible.

In patients with deficiency of glucose-6-phosphate dehydrogenase, when unithiol is used, hemolysis is possible (which can be very serious). In patients with a high risk of glucose-6-phosphate dehydrogenase deficiency, a preliminary examination and control of the possibility of hemolysis during drug therapy is necessary.

Effect on the ability to drive transp. cf. and fur:

Data confirming the effect of the drug on the ability to engage in potentially hazardous activities that require increased attention, no.

Form release / dosage:

Solution for intramuscular and subcutaneous administration, 50 mg / ml.

Packaging:

5 ml per ampoule of neutral glass.

5 ampoules of the drug are placed in a contour cell pack.

1 or 2 contoured cell packs with ampoules of the preparation together with the instruction for use and the ampoule or ampoule ampoule with a knife are placed in a pack of cardboard. When packing ampoules that have a notch, a break ring or an opening point, the ampoule knife or scarifier does not fit into the pack.

Packing for hospitals. According to 50, 100 contour cell packs with ampoules of the preparation together with instructions for use in the number of copies equal to the number of contiguous cell packs, they are placed in a box of corrugated cardboard.

Storage conditions:

Store in a dark place at a temperature of 2 to 25 ° C.

Keep out of the reach of children.

Shelf life:

5 years.

Do not use after expiry date.

Terms of leave from pharmacies:On prescription

Registration number:LP-004012

Date of registration:08.12.2016

Expiration Date:08.12.2021

The owner of the registration certificate:Kursk Biofactory - BIOK, FKPKursk Biofactory - BIOK, FKP Russia

Manufacturer: & nbsp

Kursk Biofactory - BIOK, FKP Russia

Information update date: & nbsp19.01.2017

Illustrated instructions

Instructions

Unithiol (Unithiol)